Send us a text

Stephen Harrison joins Louise Campbell and Roger Green for an insight-laden episode about challenges and opportunities in NASH drug development. This conversation continues from the preceding discussion on screen fail rates. Louise starts by asking what would the ideal patient look like for an attempt at lowering screen fail rates. Stephen responds with two assertions. The first suggestion is that higher hemoglobin A1C is indicative of disease activity in the fibrosis needed to qualify. Second, Stephen identifies utility in retrieving a FibroScan-AST score as a promising prescreen strategy. From here the conversation considers the variability of liver biopsy and whether there is a convincing impetus for establishing guidelines on the biopsy reading process. As the session winds down, Roger raises the idea that hepatocellular ballooning should be considered as a continuous variable. This proposition primes the following and final conversation to dive deep into the science and art of pathology reading.

If you enjoy the episode, have questions or interest around NASH therapeutic development, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at [email protected].

Stay Safe and Surf On!